Overview

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

Status:
Completed
Trial end date:
2020-05-11
Target enrollment:
Participant gender:
Summary
Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
Phase:
Phase 2
Details
Lead Sponsor:
Chonnam National University Hospital
Treatments:
Afatinib